Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations

Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) were developed to overcome EGFR T790M-mediated resistance to first- and second-generation EGFR-TKIs. Third-generation EGFR-TKIs, such as osimertinib and nazartinib, are effective for patients with the EGF...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Masuzawa, Keita, Yasuda, Hiroyuki, Hamamoto, Junko, Nukaga, Shigenari, Hirano, Toshiyuki, Kawada, Ichiro, Naoki, Katsuhiko, Soejima, Kenzo, Betsuyaku, Tomoko
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739653/
https://ncbi.nlm.nih.gov/pubmed/29285266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22297
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars